Groot-Loonen J J, Otten B J, van t' Hof M A, Lippens R J, Stoelinga G B
Department of Pediatric Oncology, University of Nijmegen, The Netherlands.
Pediatrics. 1995 Oct;96(4 Pt 1):693-5.
In children treated for acute lymphoblastic leukemia (ALL), catch-up growth occurs after cessation of therapy and not during maintenance therapy. In this study we investigated whether this inhibition of catch-up growth during maintenance treatment is attributable to the influence of chemotherapy or to the influence of corticosteroids.
Forty-six children treated for ALL were included in the study. In 27 patients maintenance therapy comprised vincristine (VCR), prednisone (Pred), or dexamethasone (Dexa) alternated with 6-mercaptopurine (6-MP) and methotrexate (MTX) and 19 patients received maintenance therapy with 6-MP and MTX only. Treatment did not include cranial irradiation.
Statural growth during maintenance treatment was comparable in both groups over the study period of 1.5 years.
Chemotherapy with 6-MP and MTX, and not corticosteroids, is the main factor that prevents catch-up growth from occurring during maintenance therapy for ALL.
在接受急性淋巴细胞白血病（ALL）治疗的儿童中，追赶生长发生在治疗停止后而非维持治疗期间。在本研究中，我们调查了维持治疗期间追赶生长的抑制是归因于化疗的影响还是皮质类固醇的影响。
46名接受ALL治疗的儿童被纳入研究。27名患者的维持治疗包括长春新碱（VCR）、泼尼松（Pred）或地塞米松（Dexa）与6-巯基嘌呤（6-MP）和甲氨蝶呤（MTX）交替使用，19名患者仅接受6-MP和MTX的维持治疗。治疗不包括颅脑照射。
在1.5年的研究期间，两组患者维持治疗期间的身高增长相当。
6-MP和MTX化疗而非皮质类固醇是ALL维持治疗期间阻止追赶生长发生的主要因素。
